Loading organizations...
§ Private Profile · 600 Suffolk St Suite 250, Lowell, Massachusetts 01854, US
clinical-stage biopharma develops oral polymer therapies targeting GI tract for type 2 diabetes & obesity.
Glyscend Therapeutics is a clinical-stage biopharmaceutical company based in Lowell, Massachusetts, that develops oral, polymer-based therapies targeting the gastrointestinal tract to treat metabolic disorders like type 2 diabetes and obesity. The organization's experimental pharmacological treatments are specifically designed to mimic the metabolic benefits of bariatric surgery, facilitating significant weight loss and improved glucose control without requiring invasive surgical procedures. Operating with a lean team of approximately seven employees, the firm advances its clinical pipeline through institutional venture capital backing and early-stage research grants. Glyscend secured $20.5 million in Series A funding during early 2020, drawing equity investments from recognizable financial backers including Brandon Capital Partners, Santé Ventures, and the Thiel Foundation's Breakout Labs. Following initial scientific research conducted at Johns Hopkins University, the enterprise was officially founded in 2014 by Kevin Colbert and Ashish Nimgaonkar.
Glyscend Therapeutics has raised $20.0M across 1 funding round.
Glyscend Therapeutics has raised $20.0M in total across 1 funding round.
Glyscend Therapeutics has raised $20.0M in total across 1 funding round.
Glyscend Therapeutics's investors include Santé Ventures, Bob Soh, Brandon Capital Partners.
Glyscend Therapeutics has raised $20.0M across 1 funding round. Most recently, it raised $20.0M Series A in June 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2020 | $20M Series A | Santé Ventures, BOB SOH | Brandon Capital Partners | Announced |
Glyscend Therapeutics is a clinical-stage biotechnology company developing oral, gut-targeted polymer therapies to treat type 2 diabetes (T2D) and obesity by mimicking the metabolic benefits of bariatric surgery without invasive procedures.[1][2][3] Its lead candidate, GLY-200, is a proprietary polymer drug that creates a dynamic barrier in the gut for "duodenal exclusion," reducing postprandial glucose and body weight, as shown in Phase 1 and Phase 2a trials, with a Phase 2 obesity trial dosing its first patient in June 2024.[2][3][4] Glyscend serves patients with T2D, overweight, or obesity, addressing the need for non-surgical alternatives amid rising metabolic disease prevalence, backed by a team experienced in over 25 FDA-approved products like Byetta and Renagel.[1][3]
The company operates from Baltimore, Maryland (with Boston announcements), employs under 25 people, and generates under $5 million in revenue, focusing on advancing GLY-200 into Phase 2b while leveraging its novel mechanism for broader metabolic conditions.[1][2]
Glyscend emerged from expertise in gastroenterology, metabolism, polymer chemistry, and drug development, with founders and team members contributing to over 25 FDA-approved therapies, including first-in-class drugs like Byetta®, Bydureon®, Renagel®, and Welchol®.[1][3] The core idea stemmed from replicating bariatric surgery's "duodenal exclusion" physiology via oral polymers, providing gastric bypass benefits non-invasively.[2][3]
Pivotal early moments include FDA clearance of an IND for GLY-200 in 2022, positive Phase 1 biomarker data that year, and Phase 2a results in 2023 showing clinically relevant glucose and weight reductions.[2] Leadership transitioned in September 2023 with Sapan Shah, Ph.D., appointed CEO, bringing 25+ years in life sciences to accelerate growth.[2]
Glyscend rides the exploding demand for obesity and T2D treatments, fueled by GLP-1 drugs like semaglutide but seeking oral, surgery-mimicking alternatives amid 1 billion+ global obesity cases.[1][2] Timing aligns with post-2020 biotech surge in metabolic innovation, where non-invasive options address surgery's risks and access barriers.[3]
Market forces favor it: aging populations, rising T2D/obesity rates, and investor interest in polymer platforms for chronic diseases.[1][5] Glyscend influences the ecosystem by pioneering "pharmacologic duodenal exclusion," potentially expanding to other gut-mediated conditions and complementing injectables with easier adherence.[2][3]
Glyscend's Phase 2 data will be pivotal; success could propel GLY-200 to Phase 3 by 2026-2027, attracting partnerships amid obesity market growth to $100B+.[2][4] Trends like AI-optimized polymers and combo therapies with GLP-1s may shape its path, evolving its influence from niche biotech to metabolic leader. This positions Glyscend to deliver bariatric benefits at scale, transforming T2D/obesity care as queried.